FDA's Waning Foreign Inspections Preceded Cyclospora Outbreak

A Cyclospora outbreak has emerged against a backdrop of steadily shrinking FDA oversight of foreign food production facilities, a pattern that raises urgent questions about the agency's capacity to catch contamination before it reaches American tables.

The timing is not coincidental. Over the past several years, the number of inspections the Food and Drug Administration conducts at food facilities outside the United States has declined measurably. This erosion of preventive capacity means fewer opportunities for regulators to identify unsafe practices, verify sanitation standards, or trace the source of pathogens before they contaminate produce or other foods destined for U.S. consumers. When an outbreak occurs, investigators are left working backward from illness rather than forward from prevention.

Cyclospora, a parasite that causes severe gastrointestinal illness, has been linked to imported produce in previous outbreaks. The current outbreak has sickened consumers across multiple states, though the full scope of cases and their severity remain under investigation. What is clear is that the FDA's reduced foreign inspection footprint may have limited the agency's ability to identify the contamination source early or to enforce corrective measures at the point of origin.

The decline in foreign inspections reflects broader resource constraints at the FDA. The agency oversees an enormous food supply—much of it now sourced internationally—with a budget and staffing level that has not kept pace with the complexity of global food networks. Foreign inspections require travel, coordination with host countries, and specialized expertise. When resources tighten, these inspections are often the first to be deferred or delayed.

Food safety experts have long warned that this approach inverts the logic of public health. It is far cheaper and more effective to prevent contamination at the source than to respond to outbreaks after people have fallen ill. An inspection that catches a sanitation problem at a foreign farm prevents hospitalizations, lost productivity, and the cascade of costs that follow a widespread outbreak. Yet the trend has moved in the opposite direction.

The FDA has acknowledged the inspection decline but has not announced a comprehensive plan to reverse it. The agency faces competing demands—new regulations to implement, domestic facility inspections to conduct, and emerging food safety threats to monitor. Without additional resources or a significant reallocation of existing ones, the gap between the agency's responsibilities and its capacity will likely persist.

For consumers, the practical effect is a food system with fewer checkpoints. Produce arrives at distribution centers with less certainty that it has been inspected for safety. When illness clusters appear, investigators must work harder to trace the source. And for the people who become sick—experiencing days of severe illness, potential hospitalization, and long-term complications—the outbreak represents a failure of prevention that might have been avoidable. The question now is whether this outbreak will prompt a recalibration of FDA priorities and resources, or whether foreign inspections will continue to decline as other pressures mount.